Axel Rominger
Overview
Explore the profile of Axel Rominger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
288
Citations
4514
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chen Y, Shao X, Shi K, Rominger A, Caobelli F
Semin Nucl Med
. 2025 Feb;
PMID: 40011118
Breast cancer is one of the most common types of cancer affecting women worldwide. Artificial intelligence (AI) is transforming breast cancer imaging by enhancing diagnostic capabilities across multiple imaging modalities...
2.
Wang M, Lu J, Li L, Liu F, Jiao F, Wu P, et al.
Eur Radiol
. 2025 Feb;
PMID: 40000508
Objectives: Considerable evidence suggests that midbrain-based magnetic resonance Parkinsonism index (MRPI) measurements are reliable biomarkers for the diagnosis of progressive supranuclear palsy (PSP). However, the longitudinal atrophy pattern of PSP...
3.
Ryhiner M, Song Y, Hong J, Ferreira C, Rominger A, Kossatz S, et al.
Eur J Nucl Med Mol Imaging
. 2025 Feb;
PMID: 40000461
Background: Although the combined treatment with radiopharmaceutical therapy (RPT) and poly (ADP-ribose) polymerase inhibitors (PARPi) shows promise, a critical challenge remains in the limited quantitative understanding needed to optimize treatment...
4.
Bilinska A, Ballal S, Bal C, Lappchen T, Pilatis E, Menendez E, et al.
Eur J Nucl Med Mol Imaging
. 2025 Feb;
PMID: 40000459
Purpose: This study explores the use of fibroblast activation protein inhibitors (FAPI) targeting radiopharmaceuticals as a new approach for pan-cancer treatment, focusing on key factors affecting their effectiveness. We hypothesized...
5.
Lu Z, Hu J, Chen G, Jiang H, Shih C, Afshar-Oromieh A, et al.
Med Phys
. 2025 Feb;
PMID: 39935268
Background: Bone marrow (BM) is the dominant dose-limiting organ in [Lu]Lu-PSMA-617 therapy for patients with metastasized castration resistant prostate cancer, where BM dosimetry is challenging due to segmentation. Purpose: We...
6.
Lopes L, Lopez-Montes A, Chen Y, Koller P, Rathod N, Blomgren A, et al.
Semin Nucl Med
. 2025 Feb;
PMID: 39934005
Nuclear medicine has continuously evolved since its beginnings, constantly improving the diagnosis and treatment of various diseases. The integration of artificial intelligence (AI) is one of the latest revolutionizing chapters,...
7.
Laurent B, Bousse A, Merlin T, Rominger A, Shi K, Visvikis D
Eur J Nucl Med Mol Imaging
. 2025 Feb;
PMID: 39918764
Objective: Long-axial field-of-view (LAFOV) positron emission tomography (PET) systems allow higher sensitivity, with an increased number of detected lines of response induced by a larger angle of acceptance. However this...
8.
Ma Q, Chen B, Seifert R, Zhou R, Xiao L, Yang J, et al.
Eur J Nucl Med Mol Imaging
. 2025 Jan;
PMID: 39865180
Purpose: To develop and validate a prostate-specific membrane antigen (PSMA) PET/CT based multimodal deep learning model for predicting pathological lymph node invasion (LNI) in prostate cancer (PCa) patients identified as...
9.
Li Y, Yang J, Xiao L, Zhou M, Li J, Cai Y, et al.
Eur J Nucl Med Mol Imaging
. 2025 Jan;
PMID: 39862259
Purpose: This study aimed to identify if a subset of men can safely avoid or delay prostate biopsy based on negative results of prostate-specific membrane antigen positron emission tomography (PSMA-PET)....
10.
Li R, Xiao L, Han H, Long H, Liao W, Yang Z, et al.
Eur J Nucl Med Mol Imaging
. 2025 Jan;
PMID: 39777496
Purpose: Temporal lobe epilepsy (TLE) is a brain network disorder closely associated with synaptic loss and has a genetic basis. However, the in vivo whole-brain synaptic changes at the network-level...